Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

TY - JOUR

T1 - Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

AU - Styczynski, Jan

AU - Tridello, Gloria

AU - Gil, Lidia

AU - Ljungman, Per

AU - Mikulska, Malgorzata

AU - Ward, Katherine N

AU - Cordonnier, Catherine

AU - de la Camara, Rafael

AU - Averbuch, Diana

AU - Knelange, Nina

AU - Socié, Gerard

AU - Chevallier, Patrice

AU - Blaise, Didier

AU - Yakoub-Agha, Ibrahim

AU - Forcade, Edouard

AU - Cornelissen, Jan

AU - Maertens, Johan

AU - Petersen, Eefke

AU - Nguyen-Quoc, Stéphanie

AU - Veelken, Hendrik

AU - Schaap, Nicolaas

AU - Passweg, Jakob

AU - Michallet, Mauricette

AU - Fegueux, Nathalie

AU - Deconinck, Eric

AU - Russell, Nigel

AU - Basak, Grzegorz

AU - Bader, Peter

AU - Montoto, Silvia

AU - Kröger, Nicolaus

AU - Cesaro, Simone

AU - Infectious Diseases Working Party EBMT

PY - 2019/12

Y1 - 2019/12

N2 - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.

AB - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.

U2 - 10.1038/s41409-019-0627-9

DO - 10.1038/s41409-019-0627-9

M3 - SCORING: Journal article

C2 - 31363166

VL - 54

SP - 2060

EP - 2071

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -